There is only ONE criteria that should determine t
Post# of 148188
(Total Views: 641)
Posted On: 10/10/2020 3:52:12 PM
There is only ONE criteria that should determine the DSMB's decision to allow an EUA for Leronlimab in my opinion - IS IT SAFE!
In these extraordinary, EMERGENCY times, with the suffering incurred by the virus and a limping economy, efficacy should not be the first priority for approval.
Any and everything that is safe should be tried to stop this pandemic. Efficacy is, of course, highly important but is not a sufficient reason now for lack of application to the problem.
The only harm that can come from the approval of all treatments that are safe is the case of either or but not both - ie, the crowding out of the efficacious by the inefficacious.
If a treatment is determined to be safe, it should be on the table for anyone to try. Several treatments can be tried if possible if they don't interact. Again, the criteria is SAFETY.
There is no excuse for not giving Leronlimab EUA status, especially if it is under the cover of a Phase 4 trial period.
Dr. House would agree with me on this!
In these extraordinary, EMERGENCY times, with the suffering incurred by the virus and a limping economy, efficacy should not be the first priority for approval.
Any and everything that is safe should be tried to stop this pandemic. Efficacy is, of course, highly important but is not a sufficient reason now for lack of application to the problem.
The only harm that can come from the approval of all treatments that are safe is the case of either or but not both - ie, the crowding out of the efficacious by the inefficacious.
If a treatment is determined to be safe, it should be on the table for anyone to try. Several treatments can be tried if possible if they don't interact. Again, the criteria is SAFETY.
There is no excuse for not giving Leronlimab EUA status, especially if it is under the cover of a Phase 4 trial period.
Dr. House would agree with me on this!
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼